Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Nov;18(11):737.
doi: 10.1038/s41569-021-00627-z.

Empagliflozin improves clinical outcomes for HFpEF in EMPEROR-Preserved

Karina Huynh  1
Affiliations
Comment

Empagliflozin improves clinical outcomes for HFpEF in EMPEROR-Preserved

Karina Huynh. Nat Rev Cardiol. 2021 Nov.
No abstract available

PubMed Disclaimer

Comment on

  • Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial.
    Packer M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, Carson P, Anand I, Doehner W, Haass M, Komajda M, Miller A, Pehrson S, Teerlink JR, Brueckmann M, Jamal W, Zeller C, Schnaidt S, Zannad F. Packer M, et al. Circulation. 2021 Jan 26;143(4):326-336. doi: 10.1161/CIRCULATIONAHA.120.051783. Epub 2020 Oct 21. Circulation. 2021. PMID: 33081531 Free PMC article. Clinical Trial.
  • Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
    Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, Brunner-La Rocca HP, Choi DJ, Chopra V, Chuquiure-Valenzuela E, Giannetti N, Gomez-Mesa JE, Janssens S, Januzzi JL, Gonzalez-Juanatey JR, Merkely B, Nicholls SJ, Perrone SV, Piña IL, Ponikowski P, Senni M, Sim D, Spinar J, Squire I, Taddei S, Tsutsui H, Verma S, Vinereanu D, Zhang J, Carson P, Lam CSP, Marx N, Zeller C, Sattar N, Jamal W, Schnaidt S, Schnee JM, Brueckmann M, Pocock SJ, Zannad F, Packer M; EMPEROR-Preserved Trial Investigators. Anker SD, et al. N Engl J Med. 2021 Oct 14;385(16):1451-1461. doi: 10.1056/NEJMoa2107038. Epub 2021 Aug 27. N Engl J Med. 2021. PMID: 34449189 Clinical Trial.

References

Original articles
    1. Anker, S. D. et al. Empagliflozin in heart failure with preserved ejection fraction. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2107038 (2021) - DOI - PubMed
    1. Packer, M. et al. Effect of empagliflozin on worsening heart failure events in patients with heart failure and a preserved ejection fraction: the EMPEROR-Preserved trial. Circulation https://doi.org/10.1161/CIRCULATIONAHA.121.056824 (2021) - DOI - PubMed
Related articles
    1. Mishra, S. et al. Cellular and molecular pathobiology of heart failure with preserved ejection fraction. Nat. Rev. Cardiol. 18, 400–423 (2021) - DOI
    1. Cowie, M. R. et al. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat. Rev. Cardiol. 17, 761–772 (2020) - DOI

LinkOut - more resources